+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Reviva Pharmaceuticals Inc - logo
Alzheimer's Disease Market (2nd edition) by Type of Treatment (Symptomatic and Disease Modifying), Symptomatic Indications (Dementia, Insomnia and Other Psychological Symptoms) and Geography (North America, Europe and Asia-Pacific), 2021-2030 - Product Thumbnail Image

Alzheimer's Disease Market (2nd edition) by Type of Treatment (Symptomatic and Disease Modifying), Symptomatic Indications (Dementia, Insomnia and Other Psychological Symptoms) and Geography (North America, Europe and Asia-Pacific), 2021-2030

  • Report
  • September 2021
  • 150 Pages
From
Schizophrenia (Central Nervous System) - Drugs in Development, 2021 - Product Thumbnail Image

Schizophrenia (Central Nervous System) - Drugs in Development, 2021

  • Drug Pipelines
  • September 2021
  • 513 Pages
From
Depression (Central Nervous System) - Drugs In Development, 2021 - Product Thumbnail Image

Depression (Central Nervous System) - Drugs In Development, 2021

  • Report
  • July 2021
  • 862 Pages
From
Obesity (Metabolic Disorder) - Drugs in Development, 2021 - Product Thumbnail Image

Obesity (Metabolic Disorder) - Drugs in Development, 2021

  • Report
  • October 2021
  • 763 Pages
From
Alzheimer's Disease: Pipeline Review, Developer Landscape and Competitive Insights - Product Thumbnail Image

Alzheimer's Disease: Pipeline Review, Developer Landscape and Competitive Insights

  • Report
  • March 2019
  • 220 Pages
From
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • May 2022
  • 83 Pages
From
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • May 2022
  • 45 Pages
From
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Pipeline Review, H2 2018 - Product Thumbnail Image

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Pipeline Review, H2 2018

  • Drug Pipelines
  • November 2018
  • 70 Pages
From
Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics - Product Thumbnail Image

Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics

  • Report
  • March 2020
  • 357 Pages
From
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Pipeline Review, H2 2018 - Product Thumbnail Image

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Pipeline Review, H2 2018

  • Drug Pipelines
  • September 2018
  • 63 Pages
From
Depressive Disorders (Major Depression, Bipolar Disorder, Postpartum Depression, Treatment-Resistant Depression, and Others): Pipeline Review, Developer Landscape and Competitive Insights, 2019 - Product Thumbnail Image

Depressive Disorders (Major Depression, Bipolar Disorder, Postpartum Depression, Treatment-Resistant Depression, and Others): Pipeline Review, Developer Landscape and Competitive Insights, 2019

  • Report
  • April 2019
  • 208 Pages
From
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Pipeline Review, H1 2018 - Product Thumbnail Image

5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Pipeline Review, H1 2018

  • Drug Pipelines
  • June 2018
  • 50 Pages
From
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Pipeline Review, H1 2018 - Product Thumbnail Image

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Pipeline Review, H1 2018

  • Drug Pipelines
  • May 2018
  • 66 Pages
From
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Pipeline Review, H1 2018 - Product Thumbnail Image

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Pipeline Review, H1 2018

  • Drug Pipelines
  • March 2018
  • 69 Pages
From
Obesity - Pipeline Review, H2 2020 - Product Thumbnail Image

Obesity - Pipeline Review, H2 2020

  • Drug Pipelines
  • November 2020
  • 640 Pages
From
Schizophrenia - Pipeline Review, H2 2020 - Product Thumbnail Image

Schizophrenia - Pipeline Review, H2 2020

  • Drug Pipelines
  • November 2020
  • 440 Pages
From
Pulmonary Arterial Hypertension (Cardiovascular) - Drugs In Development, 2021 - Product Thumbnail Image

Pulmonary Arterial Hypertension (Cardiovascular) - Drugs In Development, 2021

  • Report
  • July 2021
  • 426 Pages
From
Insomnia (Central Nervous System) - Drugs in Development, 2021 - Product Thumbnail Image

Insomnia (Central Nervous System) - Drugs in Development, 2021

  • Drug Pipelines
  • September 2021
  • 169 Pages
From
Autism (Central Nervous System) - Drugs in Development, 2021 - Product Thumbnail Image

Autism (Central Nervous System) - Drugs in Development, 2021

  • Drug Pipelines
  • March 2021
From
Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets - Product Thumbnail Image

Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

  • Drug Pipelines
  • August 2019
  • 142 Pages
From
Loading Indicator